Jose Tongol, MD
Hematology & Oncology · Albany, GANPI 1821034505
Payments from drug & device makers
Across 115 payments — averaging $336.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$18K
- Pfizer$7K
- Pharmacyclics LLC, An Abbvie Company$5K
- E.r. Squibb & Sons, L.L.C.$5K
- Novartis$3K
- Amgen$158
- plus $1K from 26 others
What the payments were for
- Food & beverage$1,29578%
- Education$35922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 8 | $17,550 |
| Pfizer | 13 | $7,147 |
| Pharmacyclics LLC, An Abbvie Company | 27 | $5,100 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,875 |
| Novartis | 6 | $2,629 |
| Amgen | 8 | $158 |
| Daiichi Sankyo Inc. | 4 | $154 |
| Merck | 7 | $142 |
| AbbVie | 3 | $106 |
| Seagen Inc. | 3 | $96 |
| Incyte Corporation | 1 | $86 |
| Foundation Medicine, Inc. | 1 | $69 |
| Boehringer Ingelheim | 2 | $55 |
| AstraZeneca | 2 | $53 |
| Janssen Scientific Affairs, LLC | 1 | $53 |
| Eisai Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Verastem, Inc. | 2 | $34 |
| AMAG Pharmaceuticals, Inc. | 2 | $34 |
| Beigene USA, Inc. | 1 | $34 |
| Genentech USA, Inc. | 2 | $29 |
| Exelixis Inc. | 2 | $26 |
| GSK | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 2 | $22 |
| Tesaro, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $14 |
| Sanofi | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $11 |
How this compares
$38,712 in reported general payments places this provider in the 70th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 139 | $2,275,961 |
| RevlimidLenalidomide | 98 | $1,745,051 |
| PomalystPomalidomide | 69 | $1,563,812 |
| Lenalidomide | 89 | $1,182,340 |
| LenvimaLenvatinib Mesylate | 15 | $664,239 |
| IbrancePalbociclib | 39 | $607,275 |
| FabhaltaIptacopan Hcl | 11 | $497,266 |
| LonsurfTrifluridine/Tipiracil Hcl | 50 | $495,394 |
| JakafiRuxolitinib Phosphate | 29 | $469,865 |
| CabometyxCabozantinib S-Malate | 15 | $385,635 |
| OjjaaraMomelotinib Dihydrochloride | 13 | $359,207 |
| BrukinsaZanubrutinib | 19 | $285,104 |
| ScemblixAsciminib Hydrochloride | 13 | $271,292 |
| XtandiEnzalutamide | 12 | $173,757 |
| Imatinib Mesylate | 44 | $135,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $5,100 | $2,275,961139 claims |
| Bristol Myers SquibbRevlimid | $17,550 | $1,745,05198 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $4,875 | $1,563,81269 claims |
| NovartisFabhalta, Scemblix, Gleevec | $2,629 | $880,06736 claims |
| PfizerIbrance, Eliquis | $7,147 | $690,178167 claims |
| Eisai Inc.Lenvima | $49 | $664,23915 claims |
| Taiho Oncology, Inc.Lonsurf | $16 | $495,39450 claims |
| Incyte CorporationJakafi | $86 | $469,86529 claims |
| Exelixis Inc.Cabometyx | $26 | $385,63515 claims |
| GSKOjjaara | $25 | $359,20713 claims |
| Beigene USA, Inc.Brukinsa | $34 | $285,10419 claims |
| Johnson & JohnsonXarelto | $42 | $32,13831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Albany
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.